HK1085652A1 - Stabilized synthetic immunogen delivery system - Google Patents

Stabilized synthetic immunogen delivery system

Info

Publication number
HK1085652A1
HK1085652A1 HK06103311.0A HK06103311A HK1085652A1 HK 1085652 A1 HK1085652 A1 HK 1085652A1 HK 06103311 A HK06103311 A HK 06103311A HK 1085652 A1 HK1085652 A1 HK 1085652A1
Authority
HK
Hong Kong
Prior art keywords
immunostimulatory complex
delivery system
formulated
cells
produce
Prior art date
Application number
HK06103311.0A
Other languages
English (en)
Inventor
Kenneth K Sokoll
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of HK1085652A1 publication Critical patent/HK1085652A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK06103311.0A 2002-02-14 2006-03-14 Stabilized synthetic immunogen delivery system HK1085652A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/076,674 US8088388B2 (en) 2002-02-14 2002-02-14 Stabilized synthetic immunogen delivery system
PCT/US2003/004711 WO2003068169A2 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
US10/355,161 US8084015B2 (en) 2002-02-14 2003-05-21 Stabilized synthetic immunogen delivery system

Publications (1)

Publication Number Publication Date
HK1085652A1 true HK1085652A1 (en) 2006-09-01

Family

ID=33422414

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103311.0A HK1085652A1 (en) 2002-02-14 2006-03-14 Stabilized synthetic immunogen delivery system

Country Status (14)

Country Link
US (2) US8088388B2 (ja)
EP (1) EP1572074B1 (ja)
JP (2) JP5156170B2 (ja)
CN (2) CN101001646A (ja)
AT (1) ATE540697T1 (ja)
AU (1) AU2003213091C1 (ja)
BR (1) BRPI0307724B8 (ja)
CA (1) CA2475102C (ja)
DK (1) DK1572074T3 (ja)
ES (1) ES2383172T3 (ja)
HK (1) HK1085652A1 (ja)
MX (1) MXPA04007935A (ja)
TW (1) TWI359025B (ja)
WO (1) WO2003068169A2 (ja)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20090030309A1 (en) 2007-07-26 2009-01-29 Senorx, Inc. Deployment of polysaccharide markers
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
WO2002041786A2 (en) 2000-11-20 2002-05-30 Senorx, Inc. Tissue site markers for in vivo imaging
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
KR20050052467A (ko) * 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
JP2007500770A (ja) * 2003-07-28 2007-01-18 マリンクロッド・インコーポレイテッド 改善されたステアレート組成物およびその製法
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
US8052658B2 (en) 2005-10-07 2011-11-08 Bard Peripheral Vascular, Inc. Drug-eluting tissue marker
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8064987B2 (en) 2006-10-23 2011-11-22 C. R. Bard, Inc. Breast marker
EP3542748B1 (en) 2006-12-12 2023-08-16 C. R. Bard, Inc. Multiple imaging mode tissue marker
ES2432572T3 (es) 2006-12-18 2013-12-04 C.R. Bard, Inc. Marcador de biopsia con propiedades de obtención de imágenes generadas in situ
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
EP2144600A4 (en) 2007-04-04 2011-03-16 Massachusetts Inst Technology POLY (AMINIC ACID) TARGET MOLECULES
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
BRPI0817664A2 (pt) 2007-10-12 2015-03-24 Massachusetts Inst Technology Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
DE102008024470B4 (de) * 2008-05-21 2022-10-20 Faurecia Emissions Control Technologies, Germany Gmbh Verfahren zum Regenerieren eines Abgasreinigungsfilters sowie Verdampfer
HUE028921T2 (en) 2008-06-27 2017-01-30 Zoetis Services Llc New adjuvant preparations
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
KR101644221B1 (ko) 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
MX2011012597A (es) 2009-05-27 2012-04-19 Selecta Biosciences Inc Nanoportadores que poseen componentes con diferentes tasas de liberacion.
CN103936841B (zh) * 2009-06-04 2016-01-20 中牧实业股份有限公司 一种动物用肽疫苗及其制备
US20120309691A1 (en) * 2010-02-04 2012-12-06 Dapeng Zhou Tumor targeted delivery of immunomodulators by nanopolymers
EP2540311A4 (en) * 2010-02-26 2016-07-06 Univ Nagasaki COMPOSITE BODY FOR RELEASING ANTIGENS OR MEDICAMENTS
CN107080839A (zh) 2010-05-26 2017-08-22 西莱克塔生物科技公司 多价的合成纳米载体疫苗
WO2012005732A1 (en) 2010-07-08 2012-01-12 United Biomedical, Inc Designer peptide-based pcv2 vaccine
US20120070459A1 (en) * 2010-09-22 2012-03-22 Goovaerts Daniel G E Method for keeping a foot-and-mouth disease vaccine available for emergency vaccination
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
JP5930146B2 (ja) * 2011-03-28 2016-06-08 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
AU2011384799A1 (en) 2011-12-30 2014-07-03 United Biomedical, Inc. Synthetic peptide-based marker vaccine and diagnostic system for effective control of porcine reproductive and respiratory syndrome (PRRS)
CN104244973B (zh) 2012-11-16 2017-10-20 美国联合生物医学公司 针对口蹄疫(fmd)的基于合成肽的紧急疫苗
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
EP3046580A2 (en) * 2013-09-19 2016-07-27 Zoetis Services LLC Oil-based adjuvants
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
CN105906693B (zh) * 2014-03-07 2020-01-14 中牧实业股份有限公司 合成肽疫苗及其制备方法与应用
EP3508198A1 (en) 2014-06-04 2019-07-10 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2956065C (en) * 2014-07-25 2021-05-18 United Biomedical, Inc. Immunogenic lhrh composition and use thereof in pigs
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9502964B2 (en) * 2014-12-16 2016-11-22 Intel Corporation Systems and methods for skewing DC/DC converter phases to mitigate spurs
US10478487B2 (en) * 2015-01-16 2019-11-19 Zoetis Services Llc Foot-and-mouth disease vaccine
AU2016218254B2 (en) * 2015-02-09 2019-12-19 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
CA2992892C (en) * 2015-07-20 2019-12-31 Zoetis Services Llc Liposomal adjuvant compositions
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
KR20210068602A (ko) 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
GB8921470D0 (en) 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
AU659482B2 (en) 1991-06-28 1995-05-18 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
DK0708656T3 (da) * 1993-04-27 2002-12-02 United Biomedical Inc Antigene LHRH peptidkonstruktioner og universelle syntetiske immunstimulatorer til vacciner
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
ATE420171T1 (de) * 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1999009956A1 (en) * 1997-08-29 1999-03-04 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
US6573238B2 (en) * 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
JP2002518033A (ja) 1998-06-20 2002-06-25 ユナイティド バイオメディカル インコーポレイティド 農場動物の成長促進のための合成ソマトスタチン免疫原
WO2000050006A2 (en) * 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
DK1221955T3 (da) * 1999-09-25 2006-01-30 Univ Iowa Res Found Immunstimulerende nukleinsyre
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
IL152959A0 (en) * 2000-06-08 2003-06-24 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunostimulatory oligodeoxynucleotides
PT1296714E (pt) * 2000-06-22 2009-10-15 Coley Pharm Gmbh Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
US20040185055A1 (en) * 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
SI1651265T1 (sl) * 2003-07-24 2008-10-31 Merial Ltd Formulacije cepiva, ki obsegajo emulzijo olje v vodi

Also Published As

Publication number Publication date
DK1572074T3 (da) 2012-05-07
WO2003068169A2 (en) 2003-08-21
US8084015B2 (en) 2011-12-27
CA2475102A1 (en) 2003-08-21
ES2383172T3 (es) 2012-06-18
CN101001646A (zh) 2007-07-18
CN101001646B (zh) 2014-01-01
AU2003213091A1 (en) 2003-09-04
JP5237997B2 (ja) 2013-07-17
BRPI0307724B8 (pt) 2021-05-25
ATE540697T1 (de) 2012-01-15
TWI359025B (en) 2012-03-01
US8088388B2 (en) 2012-01-03
BR0307724A (pt) 2007-04-27
AU2003213091B2 (en) 2008-06-05
BRPI0307724B1 (pt) 2019-06-18
US20030165478A1 (en) 2003-09-04
MXPA04007935A (es) 2005-06-08
TW200307557A (en) 2003-12-16
EP1572074B1 (en) 2012-01-11
JP5156170B2 (ja) 2013-03-06
EP1572074A4 (en) 2008-04-30
WO2003068169A3 (en) 2007-03-15
AU2003213091C1 (en) 2009-01-08
US20040009897A1 (en) 2004-01-15
CA2475102C (en) 2013-04-23
JP2005530690A (ja) 2005-10-13
EP1572074A2 (en) 2005-09-14
JP2010265291A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
HK1085652A1 (en) Stabilized synthetic immunogen delivery system
TR200100936T2 (tr) Terapötik aşılama
MY125202A (en) Vaccine
IL145982A0 (en) Vaccines
EP1546206A4 (en) NOVEL IMMUNOGENIC LIPOPEPTIDES COMPRISING AUXILIARY T CELL EPITOPES AND CYTOTOXIC T LYMPHOCYTES (CTL)
GB0025577D0 (en) Vaccine
GEP20053658B (en) Soluble CTLA4 Mutant Molecules and Uses Thereof
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
EP1150710A4 (en) IMMUNOGENOUS COMPLEXES AND METHODS RELATING TO THESE
EP2298927A3 (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
AU2599002A (en) Fusion cells and cytokine compositions for treatment of disease
WO2003080111A3 (en) Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
ITVA20020024A1 (it) Prodotti per l'edilizia a base di idrossialchilguaro idrofobizzato purificato
WO2004005325A3 (en) Antigen-polymer compositions
NO20030073D0 (no) Legemiddelleveringssystem for legemidler som er lite vannopplöselige
MXPA03010261A (es) Metodos para tratar cancer.
WO2000012122A3 (de) Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
AU2003245781A8 (en) Mhc class ii peptide epitope of 5t4 antigen
IL148741A0 (en) Vaccine
EP1035133A3 (en) Fusion proteins comprising carriers that can induce a dual immune response
MY127452A (en) Vaccines.
SG142165A1 (en) Biologically active peptides

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230210